Thalidomide-induced hemorrhagic rash in a patient with myelofibrosis and delta-granule storage pool disease.

Abstract	Thalidomide is one of the immunomodulating agents used in current oncology practice. We present a case of hemorrhagic rash induced by thalidomide in a patient with delta granule storage pool disease. The patient was getting thalidomide for underlying myelofibrosis.
Authors	Asma Taj, Kamal Abbi, Roland T Skeel
Journal	American journal of therapeutics (Am J Ther) 2015 Jan-Feb Vol. 22 Issue 1 Pg. e6-7 ISSN: 1536-3686 [Electronic] United States
PMID	24105355 (Publication Type: Case Reports, Journal Article)
Chemical References	Immunosuppressive Agents Thalidomide
Topics	Aged Albinism (pathology) Drug Eruptions (etiology, pathology) Female Hemorrhage (chemically induced, pathology) Hemorrhagic Disorders (pathology) Hermanski-Pudlak Syndrome (pathology) Humans Immunosuppressive Agents (adverse effects, therapeutic use) Primary Myelofibrosis (drug therapy) Skin Diseases, Vascular (chemically induced, pathology) Thalidomide (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!